Search details
1.
Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
CA Cancer J Clin
; 69(4): 280-304, 2019 07.
Article
in English
| MEDLINE | ID: mdl-31099893
2.
Survival with Cemiplimab in Recurrent Cervical Cancer.
N Engl J Med
; 386(6): 544-555, 2022 02 10.
Article
in English
| MEDLINE | ID: mdl-35139273
3.
Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
Gynecol Oncol
; 187: 92-97, 2024 May 11.
Article
in English
| MEDLINE | ID: mdl-38735145
4.
High grade adverse event reporting and enrolment in gynecologic oncology clinical trials.
Gynecol Oncol
; 185: 1-7, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38342004
5.
HER2-low and Overexpression in Mucinous Ovarian Cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring.
Int J Gynecol Pathol
; 43(3): 275-283, 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38436360
6.
Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancers.
Int J Gynecol Cancer
; 2024 May 31.
Article
in English
| MEDLINE | ID: mdl-38821545
7.
Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.
Proc Natl Acad Sci U S A
; 118(25)2021 06 22.
Article
in English
| MEDLINE | ID: mdl-34161278
8.
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment.
Semin Cancer Biol
; 86(Pt 3): 207-223, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35395389
9.
Safety of fertility sparing management in invasive mucinous ovarian carcinoma.
Gynecol Oncol
; 174: 129-132, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37182433
10.
Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study.
Support Care Cancer
; 31(7): 404, 2023 Jun 21.
Article
in English
| MEDLINE | ID: mdl-37341839
11.
Overcoming PARP inhibitor resistance in ovarian cancer.
Int J Gynecol Cancer
; 33(3): 364-376, 2023 03 06.
Article
in English
| MEDLINE | ID: mdl-36878566
12.
Gestational trophoblastic neoplasia: does centralization of care impact clinical management?
Int J Gynecol Cancer
; 33(11): 1724-1732, 2023 11 06.
Article
in English
| MEDLINE | ID: mdl-37723102
13.
Impact of lymphadenectomy and intra-operative tumor rupture on survival in early-stage mucinous ovarian cancers.
Int J Gynecol Cancer
; 33(5): 755-760, 2023 05 01.
Article
in English
| MEDLINE | ID: mdl-36914170
14.
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Int J Gynecol Cancer
; 33(8): 1208-1214, 2023 08 07.
Article
in English
| MEDLINE | ID: mdl-37380217
15.
Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.
Can J Surg
; 66(3): E310-E320, 2023.
Article
in English
| MEDLINE | ID: mdl-37369443
16.
Management of Malignant Bowel Obstruction: An Innovative Proactive Outpatient Nurse-Led Model of Care for Patients With Advanced Gynecologic Cancer.
J Nurs Care Qual
; 38(1): 69-75, 2023.
Article
in English
| MEDLINE | ID: mdl-36214674
17.
New approaches for targeting platinum-resistant ovarian cancer.
Semin Cancer Biol
; 77: 167-181, 2021 12.
Article
in English
| MEDLINE | ID: mdl-32871277
18.
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet
; 397(10271): 281-292, 2021 01 23.
Article
in English
| MEDLINE | ID: mdl-33485453
19.
Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.
Gynecol Oncol
; 167(3): 417-422, 2022 12.
Article
in English
| MEDLINE | ID: mdl-37191644
20.
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.
Gynecol Oncol
; 167(2): 226-233, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36055813